Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Sep 20, 2019
TickeronGET DAILY SIGNALS
Three different biotech ETFs, three bearish signals with high confidence

Three different biotech ETFs, three bearish signals with high confidence

The biotech sector has been trending lower for the last five months, but has seen a bit of a rally over the last few weeks as investors appear to be making a shift from growth stocks to value stocks. Because of this rotation, many stocks in the sector are in overbought territory, at least on the daily charts. When I ran my nightly scans on Thursday night, I found three different biotech ETFs on my bearish scan and then I found that all three had seen bearish signals generated by the Tickeron Trend Prediction Engine.

The iShares Nasdaq Biotechnology ETF (Nasdaq: IBB), the Direxion Daily S&P Biotech Bull 3x Shares (AMEX: LABU), and the SPDR S&P Biotech ETF (NYSE: XBI) are the three ETFs appearing on my bearish list.

Let’s look at each one individually. The IBB has been trending lower since early April and a downward sloped trend channel has formed in the last five months. The fund just hit the upper rail of the channel and that upper rail is in the same vicinity as the 50-day moving average.

The daily stochastic readings are in overbought territory and made a bearish crossover on September 19. The bearish signal from the Tickeron Trend Prediction Engine came on September 17. The signal shows a confidence level of 71% and it shows that 85% of past predictions on the IBB have been successful. The signal calls for a decline of at least 4% within the next month.

In addition to bearish signal from Tickeron, the technical analysis overview shows that the price moved below its 50-day Moving Average, which indicates a reversal from an uptrend to a downtrend. In 35 of 40 cases where IBB's price crossed below its 50-day Moving Average, its price fell further within the subsequent month. The odds of a continued downtrend are 88%.

Turning our attention to the leveraged LABU fund, we see that it peaked around the same time as the IBB. There trend line connecting the highs is cleaner than the upper rail of the channel on the IBB, but there isn’t a parallel lower rail that would form a channel.

Like we saw on the IBB chart, the daily stochastic readings for LABU are in overbought territory and made a bearish crossover on September 19. The Tickeron Trend Prediction Engine generated a bearish signal on September 17 as well. The signal for this ETF showed a confidence level of 80% while past predictions have been successful 97% of the time.

Additionally, the Tickeron Technical Analysis Overview shows that the higher Bollinger Band was broken. A price fall is expected as the ticker heads toward the middle band. In 37 of 38 cases where LABU's price broke its higher Bollinger Band, its price dropped further during the following month. The odds of a continued downtrend are 90%.

Finally, the chart for the XBI looks a little different from the other two ETFs. Yes, the fund peaked in April, but it has seen a trend channel form over the last three months and it just hit the upper rail of the channel this week. Like the IBB channel, the upper rail of the XBI channel is in close proximity to the 50-day moving average.

As we saw with the other two, the stochastic readings are in overbought territory and made a bearish crossover, and we have the bearish signal from Tickeron on September 17. The signal for the XBI showed a confidence level of 75% and past predictions were successful 90% of the time.

For the XBI, there were several other bearish factors on the technical analysis overview. First, the fund moved above its higher Bollinger Band on September 11, 2019. This price move signals that XBI may fall back below the higher band and head toward the middle band. In 39 of 43 cases where XBI's price broke its higher Bollinger Band, its price dropped further during the following month. The odds of a continued downtrend are 90%.

On September 12, the 50-day moving average crossed below its 200-day moving average and that indicates a sell signal, due to the trend repositioning lower. In 3 of 3 cases where XBI's 50-day moving average crossed below its 200-day moving average, its price fell further within the subsequent month. The odds of a continued downtrend are 90%.

And like we saw on the IBB, the XBI saw its price drop below the 50-day moving average, which indicates a reversal from an uptrend to a downtrend. In 36 of 42 cases where XBI's price crossed below its 50-day moving average, its price fell further within the subsequent month. The odds of a continued downtrend are 86%.

Related Ticker: IBB

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


IBB in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 16, 2026

IBB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 40 of 42 cases where IBB's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 10-day moving average for IBB crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.

Following a +4.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBB advanced for three days, in 276 of 324 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

The Aroon Indicator entered an Uptrend today. In 220 of 244 cases where IBB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBB as a result. In 74 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for IBB turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 40 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.

IBB moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

The investment seeks to track the investment results of the NYSE Biotechnology Index composed of U.S.-listed equities in the biotechnology sector. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Market Cap

The average market capitalization across the iShares Biotechnology ETF (IBB) ETF is 7.93B. The market cap for tickers in the group ranges from 25.61M to 248.92B. AMGN holds the highest valuation in this group at 248.92B. The lowest valued company is AARD at 25.61M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Biotechnology ETF (IBB) ETF was -6%. For the same ETF, the average monthly price growth was -6%, and the average quarterly price growth was 18%. INSM experienced the highest price growth at 17%, while UPB experienced the biggest fall at -43%.

Volume

The average weekly volume growth across all stocks in the iShares Biotechnology ETF (IBB) ETF was 29%. For the same stocks of the ETF, the average monthly volume growth was 25% and the average quarterly volume growth was -7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 47
Price Growth Rating: 61
SMR Rating: 87
Profit Risk Rating: 87
Seasonality Score: 11 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
SSO is a 2x daily leveraged ETF (exchange-traded fund) that seeks double the daily return of the S&P 500, while XXX is a non-leveraged, passive fund blending roughly 75% S&P 500 exposure with 25% XRP, a major cryptocurrency. Both funds charge comparable fees — about 0.87% for SSO and roughly 0.85% for XXX — but their risk profiles are fundamentally different.
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.